These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 18464780)

  • 1. Designing around patents: a guideline.
    Wang SJ
    Nat Biotechnol; 2008 May; 26(5):519-22. PubMed ID: 18464780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time waits for no man: deciding when to file a patent application in Europe.
    White NL
    Nat Biotechnol; 2007 Jun; 25(6):639-41. PubMed ID: 17557096
    [No Abstract]   [Full Text] [Related]  

  • 3. Publish and perish: what constitutes a bar under the patent laws.
    Teitelbaum R; Cohen MS
    Nat Biotechnol; 2004 Nov; 22(11):1449-51. PubMed ID: 15529168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The level of disclosure necessary for patent protection of genetic innovations.
    Berman RJ; El Schoenhard A
    Nat Biotechnol; 2004 Oct; 22(10):1307-8. PubMed ID: 15470468
    [No Abstract]   [Full Text] [Related]  

  • 5. Patents: patenting of stem cell related inventions in Europe.
    Rutz B; Yeats S
    Biotechnol J; 2006 Apr; 1(4):384-7. PubMed ID: 16892264
    [No Abstract]   [Full Text] [Related]  

  • 6. Inter partes reexamination: a potentially useful approach to challenging invalid biotechnology patents.
    Derzko NM; Behringer JW
    Nat Biotechnol; 2003 Jul; 21(7):823-5. PubMed ID: 12833101
    [No Abstract]   [Full Text] [Related]  

  • 7. ESTs stumble at the utility threshold.
    Davis PK; Kelley JJ; Caltrider SP; Heinig SJ
    Nat Biotechnol; 2005 Oct; 23(10):1227-9. PubMed ID: 16211059
    [No Abstract]   [Full Text] [Related]  

  • 8. OIG issues provider self-disclosure protocol.
    Cassidy M
    Health Care Law Mon; 1998 Nov; ():3-11. PubMed ID: 10346232
    [No Abstract]   [Full Text] [Related]  

  • 9. A level playing field for intellectual property enforcement.
    Carter S
    Med Device Technol; 2004 May; 15(4):11. PubMed ID: 15303555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of recent US Supreme Court IP ruling for nanomedicine patents.
    Kim KY
    Nanomedicine (Lond); 2008 Apr; 3(2):141-3. PubMed ID: 18373420
    [No Abstract]   [Full Text] [Related]  

  • 11. Errors in patent application sequence listings.
    Jones R
    Nat Biotechnol; 2003 Oct; 21(10):1239-40. PubMed ID: 14520406
    [No Abstract]   [Full Text] [Related]  

  • 12. New guidance on the patentability of embryonic stem cell patents in Europe.
    Fitt R
    Nat Biotechnol; 2009 Apr; 27(4):338-9. PubMed ID: 19352367
    [No Abstract]   [Full Text] [Related]  

  • 13. Changing emphasis in test for patent infringement.
    Moran P
    Med Device Technol; 2005 Mar; 16(2):28. PubMed ID: 15828498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Past versus present: the importance of tense in patent application examples.
    Potter JE; Talukder G
    Nat Biotechnol; 2003 Nov; 21(11):1397-8. PubMed ID: 14595370
    [No Abstract]   [Full Text] [Related]  

  • 15. Ten years of biotech gaffes.
    Hodgson J
    Nat Biotechnol; 2006 Mar; 24(3):270-3. PubMed ID: 16525384
    [No Abstract]   [Full Text] [Related]  

  • 16. Back-door visits and open-field inspections: some comments on the legality of inspections without owner permission.
    Sikora VA
    J Environ Health; 2002; 64(6):38-9. PubMed ID: 11826625
    [No Abstract]   [Full Text] [Related]  

  • 17. OIG issues provider self-disclosure protocol.
    Pontius CA
    MLO Med Lab Obs; 1999 Jan; 31(1):20, 56. PubMed ID: 10345434
    [No Abstract]   [Full Text] [Related]  

  • 18. Determining the meaning of claim terms.
    Auer HE
    Nat Biotechnol; 2006 Jan; 24(1):41-3. PubMed ID: 16404391
    [No Abstract]   [Full Text] [Related]  

  • 19. Inspector General discusses self-disclosure initiative in open letter.
    Roeder KH; Burnette JP
    GHA Today; 2006; 50(3):3, 9. PubMed ID: 16909749
    [No Abstract]   [Full Text] [Related]  

  • 20. Revisions to the Federal Sentencing Guidelines for organizational defendants regarding compliance and ethics programs.
    Siegel S
    Health Care Law Mon; 2005 Jan; ():3-8. PubMed ID: 15739949
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.